Drug –induced liver injury:a review

Sreya Kosanam, Revathi Boyina, Lakshmi Prasanthi N


The incidence of drug induced liver injury (DILI) is about 1/1000 to 1/10000 among patients who receive therapeutic drug doses. Drug induced hepatotoxicity is a major cause of acute and chronic liver disease. The severity of liver damage ranges from nonspecific changes in liver structure to acute liver failure, cirrhosis and liver cancer. Some common agents that can cause liver injury are acetaminophen, antibiotics, statins, INH and herbal drugs.Drug-induced hepatotoxicity can be categorized based on the pattern of liver enzyme alteration (hepatocellular, cholestatic or mixed pattern), the mechanism of hepatotoxicity (direct, immune mediated or idiosyncratic) and histologic findings on liver biopsy (steatosis or sinusoidal obstruction syndrome). Treatment options for DILI include discontinuing the drug, conservative measurements and liver transplantation in the case of non-acetaminophen induced hepatotoxicity.


Hepatotoxicity, Acetaminophen, Antibiotics, Statins

Full Text:



Larry D. Epidemiology and individual susceptibility to adverse drug reaction affecting the liver. Semin Liver Dis2002; 22: 145–55.

Rowden AK, Norvell J, Eldridge DL, Kirk MA. Updates on acetaminophen toxicity. Med Clin North Am 2005; 89:1145–59.

Navarro VJ, Senior JR. Drug related hepatotoxicity. N Engl J Med 2006; 35: 731–9.

Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007; 30: 277–94.

Biour M, Jaillon PJ. [Drug-induced hepatic diseases]. Pathol Biol (Paris) 1999;47:928–937.

Lee W. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474–485.

Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov2005;4:489–499.

Grattagliano I, Bonfrate L,Diogo CV, Wang HH, Wang DQH, Portincasa P.Biochemical mechanisms in drug-induced liver injury: certainties and doubts.World J Gastroenterol 2009;15: 4865–76.

Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4: 489–99.

Boelsterli UA. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf 2002;25: 633–48.

Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009; 16: 3041–53.

Robin MA, Le Roy M,Descatoire V, Pessayer D.Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997; 26: 23–30.

Uetrecht J. New concepts in immunology relevant to idiosyncratic drug reactions: the ‘danger hypothesis’ and innate immune system.Chem Res Toxicol 1999; 12:387–95.

Park BK, Kitteringham NR,Powell H, Pirmohamed M.Advances in molecular toxicology – towards understanding idiosyncratic drug toxicity. Toxicology2000; 153: 39–60.

Matzinger P. An innate sense of danger.Immunology 1998; 10:399–415.

Luyendyk JP, Maddox JF,Cosma GN, Ganey PE,Cockerell GL, Roth RA.Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther2003; 307: 1227–34.

Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury.Gastroenterology 2008; 134:1641–54.

Kaplowitz N. Biochemical and cellular mechanisms of toxic liver Injury. Semin Liver Dis 2002; 22: 137–44.

Zimmerman HJ. Drug-induced liver disease. Drugs. Jul 1978;16(1):25-45.

Mayoral W, Lewis JH, Zimmerman H. Drug-induced liver disease. Curr Opin Gastroenterol. May 1999;15(3):208-16.

Navarro V, Senior J. Drug-related hepatotoxicity. N Engl J Med 2006;354:731–739.

Fernandes NF, Martin RR, Schenker S. Trazodone-induced hepatotoxicity: A case report with comments on drug-induced hepatotoxicity. Am J Gastroenterol 2000;95:532–535.

Fontana RJ, McCashland TM, Benner KG, et al. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl Surg 1999;5:480–484.

Buckley NA, Whyte IM, O’Connell DL, Dawson AHJ. Oral or intravenous N-acetylcysteine: Which is the treatment of choice for acetaminophen (paracetamol) poisoning? J Toxicol Clin Toxicol 1999;37:759–767.

Black M. Acetaminophen hepatotoxicity. Gastroenterology 1980;78:382–392.

Belay ED, Bresee JS, Holman RC, et al. Reye’s syndrome in the United States from 1981 through 1997 [see comments]. N Engl J Med 1999;340:1377–1382.

Agarwal DP, Goedde HW. Human aldehyde dehydrogenases: Their role in alcoholism. Alcohol 1989;6:517–523.

Bohan A, Boyer J. Mechanisms of hepatic transport of drugs: Implications for cholestatic drug reactions. Semin Liver Dis 2002;22:123–136.

Lee WM. Acute hepatic failure. N Engl J Med 1993;329:1862–1872.

Konig SA, Schenk M, Sick C, et al. Fatal liver failure associated with valproate therapy in a patient with Friedreich’s disease: Review of valproate hepatotoxicity in adults. Epilepsia 1999;40:1036–1040.

Lullman H, Lullman R, Wasserman O. Drug-induced phospholipidosis, II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Crit Drug Rev Toxicol 1975;4:185–218.

Lewis J. Drug-induced liver disease. Med Clin North Am 2000;84:1275–1311.

Chang CC, Petrelli M, Tomashefski JF Jr, McCullough AJJ. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: A case report and review of the literature. Arch Pathol Lab Med 1999;123:251256.

Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999;286:487–491.

Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275–283.

Liddle C, Goodwin B. Regulation of hepatic drug metabolism: Role of nuclear receptors PXR and CAR. Semin Liver Dis 2002;22:115–122.

Tsagaropoou-Stinga H, Mataki-Emmanouilidon R, Karida-KavaliotiS, et al. Hepatotoxic reactions in children with severe tuberculosis treated with isoniazid-rifampin. Pediatr Infect Dis 1985;4:270–273.

Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000;4:256–261.

Kergueris MF, Bourin M, Larousse C. Pharmacokinetics of isoniazid: Influence of age. Eur J Clin Pharm 1986;30:335–340.

Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006;62:423–429.

Van Puijenbroek EP, Metselaar HJ, Berghuis PH, et al. [Acute hepatocytic necrosis during ketoconazole therapy for treatment of onychomycosis. National Foundation for Registry and Evaluation of Adverse Effects.] Ned Tijdschr Geneeskd 1998;142:2416–2418.

Leonard PA, Clegg DO, Carson CC, et al. Low dose pulse methotrexate in rheumatoid arthritis: An 8-year experience with hepatotoxicity. Clin Rheumatol 1987;6:575–582.

Leo MA, Lieber CSJ. Alcohol, vitamin A, and beta-carotene: Adverse interactions, including hepatotoxicity and carcinogenicity. Am J Clin Nutr 1999;69:1071–1085.

Cullen P. Mechanistic classification of liver injury. Toxicol Pathol 2005;33:6–8.

Jaeschke H, Gores G, Cederbaum A, et al. Mechanisms of hepatotoxicity. Toxicol Sci 2002;65:166–176.

Watkins P, Seeff L. Drug-induced liver injury: Summary of a single topic clinical research conference. Hepatology 2006;43:618–631.

Foitl DR, Hyman G, Leftowitch JH. Jaundice and intrahepatic cholestasis following high-dose megestrol acetate for breast cancer.Cancer 1989; 63:438–439.

Olsson R, Wiholm BE, Sand C, et al. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992;15:154–161.

Soe KL, Soe M, Gluud CN. [Liver pathology associated with anabolic androgenic steroids]. Ugeskr Laeger 1994;156:2585–2588.

Mathieu D, Kobeiter H, Maison P, et al. Oral contraceptive use and focal nodular hyperplasia of the liver. Gastroenterology 2000;118:560–564.

O’Connor GT, Olmstead EM, Sug K, et al. Detection of hepatotoxicity associated with methotrexate therapy for psoriasis. Arch Dermatol 1989;125:1209–1217.

DOI: http://dx.doi.org/10.7439/ijpr.v5i2.1507

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


  • There are currently no refbacks.

Copyright (c) 2015 International Journal of Pharmacological Research

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.